(VIANEWS) - Pfizer (PFE), MKS Instruments (MKSI), Photronics (PLAB) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Pfizer (PFE)
116.5% sales growth and 14.03% return on equity
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide.
Pfizer's sales growth this year is anticipated to be 93.8% and a negative 16.6% for next year.
Year-on-year quarterly revenue growth grew by 44.6%, now sitting on 46.41B for the twelve trailing months.
Volume
Today's last reported volume for Pfizer is 32468200 which is 7.58% above its average volume of 30179900.
Pfizer's sales growth for the next quarter is 116.5%. The company's growth estimates for the present quarter and the next is 50% and 154.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.03%.
Volatility
Pfizer's last day, last week, and last month's current volatility was 0.27%, 1.59%, and 1.92%, respectively.
Pfizer's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.82% (day), 2.84% (last week), and 2.84% (last month), respectively.
Pfizer's Stock Yearly Top and Bottom Value
Pfizer's stock is valued at $46.60 at 20:22 EST, way below its 52-week high of $51.86 and way above its 52-week low of $32.83.
Pfizer's Moving Average
Pfizer's worth is above its 50-day moving average of $43.80 and way higher than its 200-day moving average of $39.08.Previous days news about Pfizer(PFE)
- According to Benzinga on Wednesday, 25 August, "Apart from Canada-based cybersecurity company BlackBerry, the other stocks that are trending on the forum include Medicare Advantage provider Clover Health Investments Corp. (NASDAQ:CLOV), Wish e-commerce platform operator ContextLogic Inc. (NASDAQ:WISH), chipmaker Nvidia Corp. (NASDAQ:NVDA), Chinese e-commerce company JD.com Inc. (NASDAQ:JD) and biotechnology company Pfizer Inc. (NYSE:PFE)."
- According to FXStreet on Wednesday, 25 August, "Investors in the US have cheered news that the US Food and Drug Administration had granted full approval to the COVID-19 vaccine developed by Pfizer and BioNTech."
2. MKS Instruments (MKSI)
28.7% sales growth and 17.84% return on equity
MKS Instruments, Inc. provides instruments, systems, subsystems, and process control solutions that measure, monitor, deliver, analyze, power, and control critical parameters of manufacturing processes worldwide.
MKS Instruments's sales growth this year is expected to be 24.3% and 7.4% for next year.
Year-on-year quarterly revenue growth grew by 29.5%, now sitting on 2.49B for the twelve trailing months.
Volume
Today's last reported volume for MKS Instruments is 227950 which is 46.51% below its average volume of 426184.
MKS Instruments's sales growth is a negative 0% for the current quarter and 28.7% for the next. The company's growth estimates for the current quarter and the next is 82.1% and 44%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.84%.
Volatility
MKS Instruments's last day, last week, and last month's current volatility was 0.78%, 0.91%, and 1.55%, respectively.
MKS Instruments's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.78% (day), 2.27% (last week), and 2.75% (last month), respectively.
MKS Instruments's Stock Yearly Top and Bottom Value
MKS Instruments's stock is valued at $144.04 at 20:22 EST, way below its 52-week high of $199.44 and way higher than its 52-week low of $101.78.
MKS Instruments's Moving Average
MKS Instruments's worth is under its 50-day moving average of $155.96 and way below its 200-day moving average of $170.98.3. Photronics (PLAB)
16.6% sales growth and 4.94% return on equity
Photronics, Inc., together with its subsidiaries, engages in the manufacture and sale of photomask products and services in the United States, Taiwan, Korea, Europe, China, and internationally.
Photronics's sales growth this year is expected to be 7.3% and 6.5% for next year.
Year-on-year quarterly revenue growth grew by 11.9%, now sitting on 619.01M for the twelve trailing months.
Volume
Today's last reported volume for Photronics is 468140 which is 14.66% above its average volume of 408260.
Photronics's sales growth is a negative 0% for the ongoing quarter and 16.6% for the next. The company's growth estimates for the ongoing quarter and the next is 29.4% and 150%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.94%.
Volatility
Photronics's last day, last week, and last month's current volatility was 0.29%, 1.00%, and 0.85%, respectively.
Photronics's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 6.63% (day), 3.71% (last week), and 2.54% (last month), respectively.
Photronics's Stock Yearly Top and Bottom Value
Photronics's stock is valued at $13.57 at 20:22 EST, below its 52-week high of $14.56 and way above its 52-week low of $8.64.
Photronics's Moving Average
Photronics's worth is above its 50-day moving average of $13.14 and above its 200-day moving average of $12.90.Previous days news about Photronics(PLAB)
- According to Benzinga on Wednesday, 25 August, "• Photronics (NASDAQ:PLAB) is estimated to report quarterly earnings at $0.22 per share on revenue of $168.33 million."
4. PAE Incorporated (PAE)
16.5% sales growth and 11.04% return on equity
PAE Incorporated provides operational solutions and outsourced services for the United States government, other allied governments, international organizations, and companies.
PAE Incorporated's sales growth this year is expected to be 14% and 3.9% for next year.
Year-on-year quarterly revenue growth grew by 21.3%, now sitting on 2.85B for the twelve trailing months.
Volume
Today's last reported volume for PAE Incorporated is 628323 which is 39.7% above its average volume of 449736.
PAE Incorporated's sales growth for the next quarter is 16.5%. The company's growth estimates for the ongoing quarter and the next is a negative 0% and 72.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.04%.
PAE Incorporated's Stock Yearly Top and Bottom Value
PAE Incorporated's stock is valued at $6.60 at 20:22 EST, way below its 52-week high of $10.69 and above its 52-week low of $6.47.